TL 13-110

Pricing Availability   Qty
说明: Negative control for TL 13-112 (Cat. No. 6745)
化学名: N-(2-(2-(2-(4-(4-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)ethoxy)ethoxy)ethyl)-2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)amino)acetamide
纯度: ≥98% (HPLC)
说明书
引用文献
评论
文献 (2)

生物活性 for TL 13-110

TL 13-110 is a negative control for TL 13-112 (Cat. No. 6745). Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).

许可信息

Sold under license from Dana-Farber Cancer Institute

技术数据 for TL 13-110

分子量 988.59
公式 C49H62ClN9O9S
储存 Store at -20°C
纯度 ≥98% (HPLC)
CAS Number 2229037-09-4
Smiles CC(C)OC1=CC(C2CCN(CCOCCOCCNC(CNC3=CC=CC4=C3C(N(C5CCCNC5=O)C4=O)=O)=O)CC2)=C(C)C=C1NC6=NC=C(Cl)C(NC7=CC=CC=C7S(=O)(C(C)C)=O)=N6

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for TL 13-110

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 49.43 50

制备储备液 for TL 13-110

以下数据基于产品分子量 988.59。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
0.5 mM 2.02 mL 10.12 mL 20.23 mL
2.5 mM 0.4 mL 2.02 mL 4.05 mL
5 mM 0.2 mL 1.01 mL 2.02 mL
25 mM 0.04 mL 0.2 mL 0.4 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

参考文献 for TL 13-110

参考文献是支持产品生物活性的出版物。

Powell et al (2018) Chemically induced degradation of anaplastic lymphoma kinase. J.Med.Chem. 61 4249 PMID: 29660984


If you know of a relevant reference for TL 13-110, please let us know.

关键词: TL 13-110, TL 13-110 supplier, TL13-110, PROTACS, PROTAC, Proteolysis, targeted, chimeras, cereblon, E3, ubiquitin, ligase, ALK, inhibitors, degraders, negative, controls, TPD, protein, degradation, Negative, Controls, 6746, Tocris Bioscience

篇 TL 13-110 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 TL 13-110 的引用文献。 您是否知道使用了 Tocris TL 13-110 的优秀论文? 请告知我们.

TL 13-110 的评论

目前没有该产品的评论。 Be the first to review TL 13-110 and earn rewards!

Have you used TL 13-110?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


TPD and Induced Proximity Research Product Guide

TPD and Induced Proximity Research Product Guide

This brochure highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation and Induced Proximity research, including:

  • Active Degraders
  • TAG Degradation Platform
  • Degrader Building Blocks
  • Assays for Protein Degradation
  • Induced Proximity Tools
Targeted Protein Degradation Poster

Targeted Protein Degradation Poster

Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia